Search

Your search keyword '"Montefiori, David"' showing total 187 results

Search Constraints

Start Over You searched for: Author "Montefiori, David" Remove constraint Author: "Montefiori, David" Publisher elsevier bv Remove constraint Publisher: elsevier bv
187 results on '"Montefiori, David"'

Search Results

1. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

2. Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction

3. SARS-CoV-2 Omicron XBB Lineage Spike Structures, Conformations, Antigenicity, and Receptor Recognition

4. Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques

5. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial

6. Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition

7. Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions

8. Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial

9. Neonatal SHIV infection in rhesus macaques elicited heterologous HIV-1-neutralizing antibodies

10. Vaccine Induction of CD4-Mimicking Broadly Neutralizing Antibody Precursors in Macaques

11. Adjuvants influence the maturation of VRC01-like antibodies during immunization

12. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

13. Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1

14. Structural diversity of the SARS-CoV-2 Omicron spike

15. Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike

16. Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody

17. mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice

19. Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies

20. Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against SARS-CoV-2 Omicron Variant

21. Structural Diversity of the SARS-CoV-2 Omicron Spike

22. Cryo-EM Structures of SARS-CoV-2 Omicron BA.2 Spike

23. Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine

24. HIV-1 Germline-Targeting Vaccine Regimen Selects for Rare Immunoglobulin Insertions and Deletions Typical of VRC01-Class Antibodies

25. Pharmacokinetic Serum Concentrations of VRC01 Correlate with Prevention of HIV-1 Acquisition

26. Towards a population-based threshold of protection for COVID-19 vaccines

27. Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination

28. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies

29. AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period

31. Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial

32. Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies

33. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

34. A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs

35. Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates

36. Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2

38. Collaboration between the Fab and Fc Contribute to Maximal Protection Against SARS-CoV-2 Following NVX-CoV2373 Subunit Vaccine with Matrix-M™ Vaccination

39. Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial

40. SARS-CoV-2 Variant B.1.1.7 is Susceptible to Neutralizing Antibodies Elicited by Ancestral Spike Vaccines

41. D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization

42. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

43. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

44. Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge

45. Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs

47. Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization

48. Anti-V2 Antibodies Virus Vulnerability Revealed by Envelope V1 Deletion in HIV Vaccine Candidates

49. Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization

50. Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial

Catalog

Books, media, physical & digital resources